Prostate Cancer UK welcomes Scottish new medicines review findings

  • In -

Prostate Cancer UK has welcomed the publication of an independent review of the system for making new medicines available on the NHS in Scotland. 

Dr Sarah Cant, Director of Policy & Strategy at Prostate Cancer UK, said:

"Prostate Cancer UK has long argued that the current system for approving new medicines in Scotland requires greater transparency, clarity and consistency. We therefore welcome the publication of this independent review, which echoes our perspective and sets out a number of detailed proposals for reform.

"In particular we welcome calls for the SMC to meet in public and to introduce arrangements to allow the voice of patients to be heard. Also - with more than a quarter of SMC approved treatments not being routinely used on the NHS - the recommendation that health boards publish their separate analyses of SMC appraisals appears another sensible step. 

"It is clear there is growing support for a more open and transparent system. We hope that the publication of this report - and the Scottish Parliament Health and Sport Committee report to follow - will be the catalysts required to kick-start the process. Prostate Cancer UK will continue to work with all partners to turn these proposals for change into a reality."